The global diamond-blackfan anemia (DBAAASE) syndrome therapeutics market for treatments for diamond-blackfan anaemia (DBAAASE) condition is anticipated to reach a staggering US$ 4.8 billion in 2023 and grow at a CAGR of 4.2% from 2023 to 2033. Because 90% of infected individuals develop hematologic difficulties during their first year of life, a rise in the incidence of blood disorders catapulted the global diamond-blackfan anemia treatment market over the historical era. Moreover, growing government R&D support, changing lifestyles, and rapidly evolving technology are anticipated to propel market growth in the forecast period.
The market for treatments for diamond-blackfan anaemia (DBAAASE) condition is anticipated to reach a staggering US$ 4.8 billion in 2023 and grow at a CAGR of 4.2% from 2023 to 2033. By the conclusion of the aforementioned period of assessment, a market valuation of US$ 7.29 billion is anticipated.
An genetic blood condition known as diamond-blackfan anaemia affects the bone marrow’s ability to produce red blood cells. It is a particular kind of bone marrow issue. It is caused by genetic mutations and is also known as acquired pure red cell aplasia. The signs of this illness include pale complexion, low bone density, low energy, quick heartbeat, odd thumbs, cleft palate, and problems with the heart and kidneys. defective erythrogenesis, DBA,
Request a Sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16433
North America dominates the diamond-blackfan anaemia syndrome therapeutics market owing to the presence of major notable stakeholders, high expendable income, increased medical costs, and an established medical sector in this region. According to a report published by Clevel and Clinic, the DBA Registry of North America, a database containing data on people who have this disorder, 25% of people with DBA die before the age of 50 from affiliated medical disorders.
DBA UK is a registered charity (1083179) that is governed by a written constitution and run by appointed volunteer groups. They offer support, research, and hope to the DBA community by bringing families together to discuss their experiences, share the most recent health history, and raise funds to assist those with DBA in the United Kingdom.
Key Takeaways from the Market Study
- Global DBAAASE syndrome therapeutics market to expand 1.5x from 2023 to 2033
- By treatment, blood transfusions to experience a growth rate of 6.9%
- Around 2 out of 5 DBAAASE syndrome therapeutics to happen across North America
- Europe to emerge as an important contributor, expected to surge at a CAGR of 3.7%
- Treatment through corticosteroids to gain equal traction as blood transfusions
“As medical science expands, treatments and therapies for a broad range of blood disorders is gaining major traction. This is boding well for the market on diamond blackfan anemia syndrome, with healthcare providers introducing a plethora of therapies and treatment approaches,” says an FMI analyst.
Request Discount @
https://www.futuremarketinsights.com/request-discount/rep-gb-16433
Key Market Players
Key players in the Diamond–Blackfan Anemia (DBA)/Aase Syndrome Therapeutics market are Sumitomo Corporation, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc, Sanofi, Merck KGaA, LEO Pharma A/S, Cipla Inc., GlaxoSmithKline plc, AstraZeneca, Abbott, Bayer AG.
- In July 2021, AstraZeneca procured Alexion Pharmaceuticals, a global biotech company. With this acquisition, the company will be able to enter the market for rare disease medicines, ushering in a new chapter. Moreover, the acquisition strengthened AstraZeneca’s scientific presence in immunology and would allow the company to continue to pioneer the discovery and development of medicines for patients with rare diseases using Alexion’s new complement-biology system and robust pipeline.
- In June 2022, Pfizer will collaborate with Sirana Pharma, a biotechnology company. The collaboration would help Pfizer recognize and validate a novel therapeutic concept for unique and severe bone diseases.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global diamond-blackfan anemia (DBAAASE) syndrome therapeutics market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
Request Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-16433
Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market Industry Survey
By Treatment:
- Corticosteroids
- Chelation Therapy
- Blood Transfusions
- Stem Cell Transplant
- Others
By End User:
- Hospitals
- Clinics
- Others
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
